A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Institut Claudius Regaud
H. Lee Moffitt Cancer Center and Research Institute
Shanghai Pharmaceuticals Holding Co., Ltd
The Lymphoma Academic Research Organisation
Wake Forest University Health Sciences
Celgene
Pfizer
University of California, San Diego
Acerta Pharma BV
University of Pittsburgh
University of Leeds
Institut Curie
Columbia University
Merck Sharp & Dohme LLC
Novartis
Merck Sharp & Dohme LLC
Shandong First Medical University
Hospices Civils de Lyon
Regeneron Pharmaceuticals
Amgen
Incyte Corporation
Jiangsu HengRui Medicine Co., Ltd.
Incyte Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Peter MacCallum Cancer Centre, Australia
Celgene
Beijing Boren Hospital
Rapa Therapeutics LLC
University Hospital Southampton NHS Foundation Trust
The First Affiliated Hospital of Soochow University
Aprea Therapeutics
MacroGenics
SecuraBio
Akeso
Juno Therapeutics, a Subsidiary of Celgene
Children's Cancer Group, China
Chinese University of Hong Kong
Celgene
SWOG Cancer Research Network
AstraZeneca
Sun Yat-sen University
Peter MacCallum Cancer Centre, Australia
University College, London
BeiGene
BeiGene
BeiGene
Seoul National University Hospital